APA (7th ed.) Citation

M, R., N, G., L, G., A, P., A, M., E, B., . . . A, C. (2022). Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice. Drug design, development and therapy, 16, 1975. https://doi.org/10.2147/DDDT.S358976

Chicago Style (17th ed.) Citation

M, Ranzenigo, et al. "Switching from a Non-Protease Inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice." Drug Design, Development and Therapy 16 (2022): 1975. https://doi.org/10.2147/DDDT.S358976.

MLA (9th ed.) Citation

M, Ranzenigo, et al. "Switching from a Non-Protease Inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice." Drug Design, Development and Therapy, vol. 16, 2022, p. 1975, https://doi.org/10.2147/DDDT.S358976.